Alcon received the rights to market JETREA, an injectable treatment of vitreomacular traction, in the US in October 2012.
More Articles on Ophthalmology:
EyeTechCare Receives $13M in Funding
10 Statistics on Ophthalmologist Compensation by Location
Flaum Eye Institute Recruits Dr. Harold Ross
Novartis Receives EU Clearance for JETREA
Alcon, the Fort Worth, Texas-based eye care division of healthcare products company Novartis, has announced that it has received European clearance for JETREA.
Nurses Shouldn’t be Middleware: Orchestrating the Future of Care with Unified Communications
Recommended Live Webinar on Dec 16, 2025 11:00 AM - 12:00 PM CST